CervoMed's stock soars 400% on promising dementia drug data. See more on insights, potential concerns, and what it means for ...

We recently shared a list of 10 Best Short Squeeze Stocks To Buy According to Analysts. In this article, we will see how ...

We recently published a list of 10 Best Short-Term Stocks To Buy Right Now. In this article, we are going to take a look at ...

The clinical-stage company on Monday said that, following "highly encouraging" 16-week extension results from the Phase 2b trial, it believes it has established proof-of-concept for neflamapimod as a ...

Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB), ...

We recently published a list of These 10 Stocks Posted Double-, Triple-Digit Gains Last Week. In this article, we are going ...

CRVO Stock - CervoMed's stock has been upgraded to a "Buy" with a $14 price target following promising results from its ...

JonesResearch upgraded CervoMed (CRVO) to Buy from Hold with a $15 price target arguing that the company’s latest data from ...

CervoMed's Phase 2b study extension shows improved cognitive outcomes with neflamapimod, leading to an analyst upgrade and ...

SciSparc Ltd. SPRC shares fell 18.1% to $0.3278 in pre-market trading. SciSparc shares gained around 27% on Monday after ...

CervoMed has announced positive results from the extension phase 2b RewinD-LB study of neflamapimod for dementia with Lewy ...

Positive 16-week extension data from Cervomed Inc.’s phase IIb in dementia with Lewy bodies followed a failure from December. New results from the Rewind-LB trial testing neflamapimod, a ...